David Loesch
Overview
Explore the profile of David Loesch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K, et al.
Lancet
. 2011 Mar;
377(9769):914-23.
PMID: 21376385
Background: Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action....
2.
Rudin C, Poirier J, Senzer N, Stephenson Jr J, Loesch D, Burroughs K, et al.
Clin Cancer Res
. 2011 Feb;
17(4):888-95.
PMID: 21304001
Purpose: Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer cell types, including small cell lung cancer. We conducted a...
3.
Loesch D, Robert N, Jones S, Elkordy M, Ilegbodu D, Asmar L
J Oncol Pract
. 2010 Sep;
2(6):268-73.
PMID: 20859353
Purpose: To determine the response rate (RR), progression-free survival (PFS), and toxicity in patients with HER-2/neu-negative metastatic breast cancer treated with first-line paclitaxel in a de-escalating dosing schedule. Patients And...
4.
Loesch D, Greco F, Senzer N, Burris H, Hainsworth J, Jones S, et al.
J Clin Oncol
. 2010 May;
28(18):2958-65.
PMID: 20479419
Purpose: This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Methods: Women (who had performance status [PS] of 0 to 1)...
5.
Richards D, Loesch D, Vukelja S, Wu H, Hyman W, Nieves J, et al.
Invest New Drugs
. 2010 Mar;
29(5):963-70.
PMID: 20352294
Purpose: Pemetrexed and pegylated liposomal doxorubicin (PLD) are clinically active as single agents and preclinically synergistic. This phase I, open-label trial evaluated the maximum tolerated dose (MTD) and safety of...
6.
Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, et al.
Clin Breast Cancer
. 2008 Jul;
8(2):178-86.
PMID: 18621615
Background: Gemcitabine and carboplatin have significant preclinical synergy, and both provide synergistic antitumor activity in metastatic breast cancer (MBC) when used in combination with trastuzumab. The gemcitabine/ cisplatin combination is...
7.
Chittoor S, Berry W, Loesch D, Logie K, Fleagle J, Mull S, et al.
Clin Genitourin Cancer
. 2007 Jan;
5(3):212-8.
PMID: 17239275
Purpose: Chemotherapy is often poorly tolerated in elderly patients or patients with poor performance status. This trial was designed to determine whether low-dose weekly docetaxel/estramustine was efficacious with acceptable toxicity....
8.
Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al.
J Clin Oncol
. 2006 Jun;
24(18):2786-92.
PMID: 16782917
Purpose: This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2-overexpressing metastatic breast cancer...
9.
Loesch D, Robert N, Asmar L, Gregurich M, ORourke M, Dakhil S, et al.
J Clin Oncol
. 2002 Sep;
20(18):3857-64.
PMID: 12228205
Purpose: To determine the activity of weekly paclitaxel plus carboplatin as first-line therapy in patients with advanced breast cancer (ABC) by assessing response rate, survival, and safety. Patients And Methods:...